To unlock the huge social benefits of these emerging health
technologies, the Chariot Fund exploits the deep clinical knowledge of world-class, not-for-profit clinical partners in India, and their ability to achieve social impact at huge scale. This is harnessed to H2O's core skills to source, develop, productise and commercialise technologies from the £300bn annual publicly funded research spend. By accelerating reduction to practice of new technologies into these high needs healthcare systems, the Chariot Fund not only secures significant social impact, but can break down barriers and catalyse adoption in developed healthcare economies.
The Chariot Fund benefits from an advisory board of global stature, chaired by Lord Crisp, the former CEO of the UK NHS and former permanent secretary at the UK Department of Health.
* Nigel Crisp (2010)Turning the World Upside Down, RSM Press.
Case Study - Eykona
Eykona now has its regulated medical imaging product in market in Europe and the US as a tool for documenting and monitoring chronic wounds such as diabetic foot ulcers. These complex 2.5D structures heal from the bottom up before closing, and volumetric measurement is essential to assess response to therapy and ensure that the best treatment is being given.